Metastatic neuroendocrine tumor of unknown primary presenting as acute pancreatitis

American Journal of the Medical Sciences

Volumn 335, Issue 4, 2008, Pages 304-306

  Dhar, Sunil ^a   Grossman, Craig E ^b   Kokroo, Tej ^a  

^a TEMPLE UNIVERSITY HOSPITAL   (United States)

^b Frankford Hospital   (United States)

Author keywords

Neuroendocrine tumor; Pancreatitis; Unknown primary

Indexed keywords

EPITHELIAL MEMBRANE ANTIGEN; SYNAPTOPHYSIN;

ACUTE PANCREATITIS; ADULT; ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; CASE REPORT; CLINICAL EXAMINATION; ELECTRON MICROSCOPY; FEMALE; HUMAN; HUMAN TISSUE; HYPERCALCEMIA; IMMUNOHISTOCHEMISTRY; NEUROENDOCRINE TUMOR;

EID: 42249089538     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e318156b6f3     Document Type: Article

References (13)

1. Hainsworth JD, Johnson DH, Greco FA. Poorly differentiated neuroendocrine carcinoma of unknown primary site. A newly recognized clinicopathologic entity. Ann Intern Med 1988;109:364-71.
2. Hainsworth JD, Wright EP, Johnson DH, et al. Poorly differentiated carcinoma of unknown primary site: clinical usefulness of immunoperoxidase staining. J Clin Oncol 1991;9:1931-8.
3. Pazdur R, Hoskins W, Wagman L. In: Pazdur R. Cancer management: a multidisciplinary approach. New York: F.A. Davis Company; 2003. p. 553-63.
4. Oliveira AM, Tazelaar HD, Myers JL, et al. Thyroid transcription factor-1 distinguishes metastatic pulmonary from well-differentiated neuroendocrine tumors of other sites. Am J Surg Pathol 2001;25:815-9.
5. Choong NW, Quevedo JF, Kaur JS. Small cell carcinoma of the urinary bladder. The Mayo Clinic experience. Cancer 2005;103:1172-8.
6. Papandreou CN, Daliani DD, Thall PF, et al. Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. J Clin Oncol 2002;20:3072-80.
7. Van Der Gaast A, Verwey J, Prins E, et al. Chemotherapy as treatment of choice in extrapulmonary undifferentiated small cell carcinomas. Cancer 1990;65:422-4.
8. Hoskins PJ, Swenerton KD, Pike JA, et al. Small-cell carcinoma of the cervix: fourteen years of experience at a single institution using a combined-modality regimen of involved-field irradiation and platinum-based combination chemotherapy. J Clin Oncol 2003;21:3495-501.
9. Mills SE, Cooper PH, Garland TA, et al. Small cell undifferentiated carcinoma of the larynx. Report of two patients and review of 13 additional cases. Cancer 1983;51:116-20.
10. Brenner B, Tang LH, Klimstra DS, et al. Small-cell carcinomas of the gastrointestinal tract: a review. J Clin Oncol 2004;22:2730-9.
11. Majhail NS, Elson P, Bukowski RM. Therapy and outcome of small cell carcinoma of the kidney: report of two cases and a systematic review of the literature. Cancer 2003;97:1436-41.
12. Hainsworth JD, Spigel DR, Litchy S, et al. Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma: a Minnie Pearl Cancer Research Network Study. J Clin Oncol 2006;24:3548-54.
13. Moertel CG, Kvols LK, O'Connell MJ, et al. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 1991;68:227-32.